Business Description
aTyr Pharma Inc
NAICS : 325414
SIC : 2836
ISIN : US0021201035
Description
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.86 | |||||
| Equity-to-Asset | 0.71 | |||||
| Debt-to-Equity | 0.21 | |||||
| Debt-to-EBITDA | -0.21 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -2.88 | |||||
| Beneish M-Score | 24.75 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -81.7 | |||||
| 3-Year EBITDA Growth Rate | 15.3 | |||||
| 3-Year EPS without NRI Growth Rate | 19 | |||||
| 3-Year FCF Growth Rate | 25.6 | |||||
| 3-Year Book Growth Rate | -20.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 60.96 | |||||
| Future 3-5Y Total Revenue Growth Rate | 604.81 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 75.78 | |||||
| 9-Day RSI | 63.06 | |||||
| 14-Day RSI | 59.18 | |||||
| 6-1 Month Momentum % | 85.89 | |||||
| 12-1 Month Momentum % | 124.44 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.41 | |||||
| Quick Ratio | 5.41 | |||||
| Cash Ratio | 4.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -79.1 | |||||
| Shareholder Yield % | -9.59 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -28958.72 | |||||
| Net Margin % | -27155.75 | |||||
| FCF Margin % | -28555.74 | |||||
| ROE % | -75.89 | |||||
| ROA % | -57.33 | |||||
| ROIC % | -383.23 | |||||
| ROC (Joel Greenblatt) % | -514.44 | |||||
| ROCE % | -70.11 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 855 | |||||
| PB Ratio | 3.98 | |||||
| Price-to-Tangible-Book | 3.98 | |||||
| EV-to-EBIT | -3.45 | |||||
| EV-to-Forward-EBIT | -2.86 | |||||
| EV-to-EBITDA | -3.55 | |||||
| EV-to-Forward-EBITDA | -2.86 | |||||
| EV-to-Revenue | 997.79 | |||||
| EV-to-Forward-Revenue | 19.21 | |||||
| EV-to-FCF | -3.44 | |||||
| Price-to-Net-Current-Asset-Value | 5.61 | |||||
| Price-to-Net-Cash | 7.12 | |||||
| Earnings Yield (Greenblatt) % | -28.99 | |||||
| FCF Yield % | -23.38 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ATYR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
aTyr Pharma Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.235 | ||
| EPS (TTM) ($) | -0.94 | ||
| Beta | 1 | ||
| Volatility % | 85.88 | ||
| 14-Day RSI | 59.18 | ||
| 14-Day ATR ($) | 0.225339 | ||
| 20-Day SMA ($) | 3.287 | ||
| 12-1 Month Momentum % | 124.44 | ||
| 52-Week Range ($) | 1.34 - 3.8001 | ||
| Shares Outstanding (Mil) | 83.94 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
aTyr Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
aTyr Pharma Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
aTyr Pharma Inc Frequently Asked Questions
What is aTyr Pharma Inc(ATYR)'s stock price today?
The current price of ATYR is $3.62. The 52 week high of ATYR is $3.80 and 52 week low is $1.34.
When is next earnings date of aTyr Pharma Inc(ATYR)?
The next earnings date of aTyr Pharma Inc(ATYR) is 2025-03-14 Est..
Does aTyr Pharma Inc(ATYR) pay dividends? If so, how much?
aTyr Pharma Inc(ATYR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers